search
Back to results

Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment

Primary Purpose

Ph-negative Adult Acute Lymphoblastic Leukemia

Status
Unknown status
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
autologous HSCT
Sponsored by
National Research Center for Hematology, Russia
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ph-negative Adult Acute Lymphoblastic Leukemia focused on measuring adult ALL, Ph-negative, dexamethasone, L-asparaginase

Eligibility Criteria

15 Years - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ph-negative precursors ALL
  • age 15-55 years
  • nontreated
  • Eastern Cooperative Oncology Group criterion status 0-3

Exclusion Criteria:

  • B-mature ALL
  • Ph-positivity
  • pretreatment
  • Eastern Cooperative Oncology Group criterion status 4

Sites / Locations

  • Russian Acute Lymphoblastic Leukemia Study group

Outcomes

Primary Outcome Measures

Proportion of adult ALL patients who tolerated the non-interrupted treatment
Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukemia efficacy in those subgroups

Secondary Outcome Measures

Toxicity of prolonged L-asparaginase in adult patients
Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukemia of those patients

Full Information

First Posted
August 31, 2010
Last Updated
March 6, 2018
Sponsor
National Research Center for Hematology, Russia
search

1. Study Identification

Unique Protocol Identification Number
NCT01193933
Brief Title
Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment
Official Title
Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Unknown status
Study Start Date
November 2008 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Research Center for Hematology, Russia

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the efficacy of its substitution by dexamethasone if blast count is 25% and more feasibility for adults of "no interruptions" protocol with 8 weeks induction and 14 weeks consolidation followed by 2-years maintenance. tolerability and efficacy in adults of the prolonged L-asparaginase application (total proposed dose 560.000 IU) feasibility and efficacy of autologous stem cell transplantation for T-cell ALL
Detailed Description
The blast count in b/m after 7 days of prednisolone >25% was shown in 64% of patients. The substitution of prednisolone by dexamethasone did not influence survival. "no interruptions" induction was performed in 48% of patients. In 19% of patients the L-asparaginase therapy was stopped due to toxicity. Autologous stem cell transplantation was done in 20% of T-cell ALL patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ph-negative Adult Acute Lymphoblastic Leukemia
Keywords
adult ALL, Ph-negative, dexamethasone, L-asparaginase

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
321 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
autologous HSCT
Intervention Description
T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
Primary Outcome Measure Information:
Title
Proportion of adult ALL patients who tolerated the non-interrupted treatment
Description
Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukemia efficacy in those subgroups
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Toxicity of prolonged L-asparaginase in adult patients
Description
Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukemia of those patients
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ph-negative precursors ALL age 15-55 years nontreated Eastern Cooperative Oncology Group criterion status 0-3 Exclusion Criteria: B-mature ALL Ph-positivity pretreatment Eastern Cooperative Oncology Group criterion status 4
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valeri G Savchenko, Professor
Organizational Affiliation
National Research Center for Hematology
Official's Role
Study Chair
Facility Information:
Facility Name
Russian Acute Lymphoblastic Leukemia Study group
City
Moscow
Country
Russian Federation

12. IPD Sharing Statement

Citations:
PubMed Identifier
33676165
Citation
Parovichnikova EN, Troitskaya VV, Gavrilina OA, Sokolov AN, Kokhno AV, Klyasova GA, Kuzmina LA, Galstyan GM, Makhinya SA, Latyshkevich OA, Kaporskaya TS, Lapin VA, Chabaeva YA, Kulikov SM, Savchenko VG; for Russian Acute Lymphoblastic Leukemia group. The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009. Leuk Res. 2021 May;104:106536. doi: 10.1016/j.leukres.2021.106536. Epub 2021 Feb 14.
Results Reference
derived
PubMed Identifier
31597157
Citation
Parovichnikova E, Troitskaya V, Sokolov A, Gavrilina O, Akhmerzaeva Z, Kuzmina L, Kliasova G, Chabaeva J, Kulikov S, Bondarenko S, Baranova O, Samoilova O, Kaplanov K, Minaeva N, Savchenko V; Russian Acute Lymphoblastic Leukemia Group. Can Less Intensive Chemotherapy and an Autotransplant Cure Adult T-Cell Acute Lymphoblastic Leukemia? Acta Haematol. 2020;143(2):131-139. doi: 10.1159/000502435. Epub 2019 Oct 9.
Results Reference
derived
PubMed Identifier
30701920
Citation
Piskunova IS, Obukhova TN, Parovichnikova EN, Kulikov SM, Troitskaya VV, Gavrilina OA, Savchenko VG. Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. Ter Arkh. 2018 Aug 17;90(7):30-37. doi: 10.26442/terarkh201890730-37.
Results Reference
derived
PubMed Identifier
28766535
Citation
Parovichnikova EN, Troitskaya VV, Sokolov AN, Bondarenko SN, Gavrilina OA, Baskhaeva GA, Biderman BV, Lukyanova IA, Kuz'mina LA, Klyasova GA, Kravchenko SK, Gribanova EO, Zvonkov EE, Akhmerzaeva ZK, Baranova OY, Kaporskaya TS, Ryltsova TV, Zotina EN, Zinina EE, Samoilova OS, Kaplanov KD, Gavrilova LV, Konstantinova TS, Lapin VA, Pristupa AS, Eluferyeva AS, Obukhova TN, Piskunova IS, Gal'tseva IV, Dvirnyk VN, Rusinov MA, Kulikov SM, Savchenko VG. [Adult B-cell acute lymphoblastic leukemias: Conclusions of the Russian prospective multicenter study ALL-2009]. Ter Arkh. 2017;89(7):10-17. doi: 10.17116/terarkh201789710-17. Russian.
Results Reference
derived
PubMed Identifier
26390721
Citation
Parovichnikova EN, Kuzmina LA, Mendeleeva LP, Klyasova GA, Troitskaya VV, Sokolov AN, Akhmerzaeva ZK, Kravchenko SK, Gribanova EO, Zvonkov EE, Bondarenko SN, Baranova OY, Ryltsova TV, Gavrilova LV, Zinina EE, Pristupa AS, Kaporskaya TS, Minaeva NV, Samoilova OS, Konstantinova TS, Lapin VA, Kaplanov KD, Kryuchkova IV, Nizamutdinova AS, Klimovich AV, Borisenkova EA, Moskov VI, Gaponova TV, Obukhova TV, Galtseva IV, Rusinov MA, Kulikov SM, Savchenko VG. [Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study]. Ter Arkh. 2015;87(7):15-25. doi: 10.17116/terarkh201587715-25. Russian.
Results Reference
derived

Learn more about this trial

Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment

We'll reach out to this number within 24 hrs